Table 3 Univariate and multivariate analyses of the variables associated with recurrence of hemoptysis in the patients treated with BAE (n = 60)

Age, years

58.7 ± 10.3

60.5 ± 10.5

0.98 (0.94–1.03)

0.437

 Female

10

17

1

–

 Male

11

22

0.90 (0.38–2.11)

0.802

BMI, kg/m²

21.2 ± 2.6

22.9 ± 3.5

0.84 (0.72–0.97)

0.017

0.87 (0.75–1.02)

History of hemoptysis ≥10 years

14

17

2.56 (1.02–6.41)

0.046

2.13 (0.82–5.52)

Extent of hemoptysis, mL

0.295

 < 100

5

14

 100–300

11

15

2.20 (0.76–6.35)

0.145

 ≥ 300

5

10

1.27 (0.37–4.45)

0.691

Smoking

3

9

0.49 (0.14–1.66)

0.248

Hypertension

4

9

0.98 (0.33–2.91)

0.964

Diabetes

1

3

0.95 (0.13–7.24)

0.962

Admission SBP, mmHg

123 (115, 137.5)

125 (114, 130)

1.02 (0.99–1.05)

0.156

Admission hemoglobin (g/L)

120.1 ± 14.3

124.59 ± 20.82

0.99 (0.97–1.01)

0.450

PLT, *10⁹/L

167.3 ± 63.5

195.67 ± 55.78

0.99 (0.99–1.00)

0.154

WBC, *10⁹/L

7.4 ± 3.2

8.30 ± 2.44

0.91 (0.76–1.08)

0.272

Number of lobes involved

5.0 (2.0, 8.5)

4.0 (2.0, 7.0)

1.07 (0.96–1.19)

0.206

Bronchial dilatation severity score

2.0 (1.0, 2.9)

1.8 (1.0, 2.6)

1.15 (0.68–1.96)

0.598

Bronchial wall thickening severity score

2.7 (1.95, 3.0)

2.3 (1.8, 3.0)

1.29 (0.69–2.41)

0.418

 Columnar or varicose

8

30

1

1

 Cystic

13

9

3.48 (1.44–8.43)

0.006

2.79 (1.12–6.96)

 PVA

17

32

1

–

 Embosphere

4

7

1.10 (0.37–3.29)

0.860

In-hospital days

5.0 (4.0, 7.5)

5.0 (4.0, 9.0)

0.95 (0.83–1.09)

0.438